ShareThis Page
Cancer ‘wonder’ drug might not be effective in early stages |

Cancer ‘wonder’ drug might not be effective in early stages

| Sunday, May 31, 2009 12:00 a.m

A “wonder” drug that fights breast, lung and colon cancer by cutting off blood supply to tumors doesn’t seem to pack the same punch in colon cancer caught early, according to research from Allegheny General Hospital presented Saturday at a national cancer conference in Florida.

Avastin, made by pharmaceutical giant Roche’s Genentech unit, did not improve the three-year survival rate in patients with early stages of colon cancer when compared with patients receiving standard chemotherapy, scientists said at the annual meeting of the American Society of Clinical Oncology in Orlando.

“It’s been approved for advanced cancer, and it was hoped that moving it into early stage colon cancer would increase the rate of cures,” said Allegheny General oncologist Dr. Norman Wolmark, lead researcher on the study. “And it didn’t.”

Through the National Surgical Adjuvant Breast and Bowel Project, based at Allegheny General, doctors at more than 250 hospitals worldwide recruited 2,710 early-stage colon cancer patients. Half were treated with one year of Avastin and chemotherapy; half received just chemotherapy.

Avastin is known by the generic name bevacizumab. Potential side effects include development of a hole in the stomach and bleeding problems that can hamper wound healing. Few patients experienced side effects in the clinical trial, with high blood pressure being the major problem, Wolmark said. Genentech helped pay for the clinical trial, as did the National Cancer Institute.

Though both groups of patients ultimately had the same outcome — about 75 percent lived three years without recurrence of cancer — patients on Avastin had 40 percent fewer cancer recurrences during the year they took the drug.

“While it was being given, it was effective,” Wolmark said. “But after it was discontinued, the benefit disappeared, raising the extremely important question whether giving it over a longer period of time would increase the benefit.”

Genentech is awaiting results of eight clinical trials to determine whether Avastin can reduce recurrence of other cancers, such as breast and lung, said spokeswoman Kristina Becker.

“We believe the results support the theory that Avastin may be an important medicine to help prevent early-stage colon cancer from returning,” she said in an e-mail. “The results provide valuable insights for future trials and we are committed to ongoing and future studies of Avastin in early-stage cancer.”

Wolmark’s team is considering conducting another clinical trial that would increase the time span during which Avastin is given for adjuvant care from one year to two or more.

“At this point I think everybody is enthusiastic about a trial that would use bevacizumab for two years,” Wolmark said. “But like any drug used over a long period of time, the risk of noncompliance increases. With each additional year, the number of patients that stop taking it grows and that’s not trivial.”

Categories: News
TribLIVE commenting policy

You are solely responsible for your comments and by using you agree to our Terms of Service.

We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.

While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.

We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers

We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.

We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.

We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.

We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.